Bliss GVS Pharma (BLISSGVS) Stock Overview
Engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
BLISSGVS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Bliss GVS Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹524.30 |
| 52 Week High | ₹553.00 |
| 52 Week Low | ₹118.00 |
| Beta | 1.13 |
| 1 Month Change | 23.47% |
| 3 Month Change | 102.46% |
| 1 Year Change | 240.85% |
| 3 Year Change | 479.02% |
| 5 Year Change | 368.75% |
| Change since IPO | 1,189.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| BLISSGVS | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 3.6% | 0.7% | 0.3% |
| 1Y | 240.9% | 13.8% | -0.09% |
Return vs Industry: BLISSGVS exceeded the Indian Pharmaceuticals industry which returned 14.4% over the past year.
Return vs Market: BLISSGVS exceeded the Indian Market which returned -2.1% over the past year.
Price Volatility
| BLISSGVS volatility | |
|---|---|
| BLISSGVS Average Weekly Movement | 8.8% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 3.9% |
Stable Share Price: BLISSGVS's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: BLISSGVS's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,033 | Shibroor Kamath | www.blissgvs.com |
Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. The company offers anti-diabetic, anti-infective, anti-inflammatory, antifungal, antihemorrhoidal, antimalarial, antiseptic, cardiovascular, dermatological, gastrointestinal, gynaecology, neoro/cns, ophthalmic, otc drugs, respiratory, urology, and supplementary drug products, as well as engages in pain management services. It exports its products.
Bliss GVS Pharma Limited Fundamentals Summary
| BLISSGVS fundamental statistics | |
|---|---|
| Market cap | ₹55.27b |
| Earnings (TTM) | ₹1.29b |
| Revenue (TTM) | ₹9.27b |
Is BLISSGVS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLISSGVS income statement (TTM) | |
|---|---|
| Revenue | ₹9.27b |
| Cost of Revenue | ₹4.48b |
| Gross Profit | ₹4.79b |
| Other Expenses | ₹3.50b |
| Earnings | ₹1.29b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 12.18 |
| Gross Margin | 51.70% |
| Net Profit Margin | 13.93% |
| Debt/Equity Ratio | 0.2% |
How did BLISSGVS perform over the long term?
See historical performance and comparisonDividends
Does BLISSGVS pay a reliable dividends?
See BLISSGVS dividend history and benchmarks| Bliss GVS Pharma dividend dates | |
|---|---|
| Ex Dividend Date | Jul 08 2026 |
| Dividend Pay Date | Aug 14 2026 |
| Days until Ex dividend | 4 days |
| Days until Dividend pay date | 33 days |
Does BLISSGVS pay a reliable dividends?
See BLISSGVS dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/10 10:54 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bliss GVS Pharma Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kameswari V. S. Chavali | FirstCall Research |
| Anil Burra | FirstCall Research |